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Background: Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid
Cancer (EXAM) trial demonstrated significant improvement in progression-free survival with cabozantinib versus placebo in
patients with progressive medullary thyroid cancer (MTC). Final analysis of overall survival (OS), a key secondary endpoint, was
carried out after long-term follow-up.
Patients and methods: EXAM compared cabozantinib with placebo in 330 patients with documented radiographic
progression of metastatic MTC. Patients were randomized (2:1) to cabozantinib (140mg/day) or placebo. Final OS and updated
safety data are reported.
Results: Minimum follow-up was 42months. Kaplan–Meier analysis showed a 5.5-month increase in median OS with
cabozantinib versus placebo (26.6 versus 21.1months) although the difference did not reach statistical significance [stratified
hazard ratio (HR), 0.85; 95% confidence interval (CI), 0.64–1.12; P¼ 0.24]. In an exploratory assessment of OS, progression-free
survival, and objective response rate, cabozantinib appeared to have a larger treatment effect in patients with RETM918T
mutation–positive tumors compared with patients not harboring this mutation. For patients with RET M918T-positive disease,
median OS was 44.3months for cabozantinib versus 18.9months for placebo [HR, 0.60; 95% CI, 0.38–0.94; P¼ 0.03 (not adjusted
for multiple subgroup analyses)], with corresponding values of 20.2 versus 21.5months (HR, 1.12; 95% CI, 0.70–1.82; P¼ 0.63) in
the RET M918T–negative subgroup. Median treatment duration was 10.8months with cabozantinib and 3.4months with
placebo. The safety profile for cabozantinib remained consistent with that of the primary analysis.
Conclusion: The secondary end point was not met in this final OS analysis from the trial of cabozantinib in patients with
metastatic, radiographically progressive MTC. A statistically nonsignificant increase in OS was observed for cabozantinib
compared with placebo. Exploratory analyses suggest that patients with RETM918T–positive tumors may experience a greater
treatment benefit with cabozantinib.
Trial Registration Number: NCT00704730
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Introduction
Medullary thyroid carcinoma (MTC) is a rare malignancy arising
from calcitonin-producing parafollicular C cells of the thyroid
gland [1, 2]. MTC accounts for 2% of all thyroid carcinomas
and up to 14% of thyroid cancer–related deaths. About half of pa-
tients with MTC present with lymph node metastases and 10%
with distant metastatic disease [3]. Survival rates vary according
to disease stage [3]. The 10-year survival rate is 96% for patients
with tumors confined to the thyroid gland but only 40% for those
with distant metastases [2].
Approximately 75% of cases of MTC occur sporadically,
whereas 25% are associated with one of two inherited autosomal
dominant syndromes—multiple endocrine neoplasia 2 A
(MEN2A) or MEN2B [3, 4]. A number of mutations and signal-
ing pathways have been implicated in MTC pathogenesis. Nearly
all patients with hereditary forms have germline mutations iden-
tified in the gene encoding the RET protein [5], and somatic RET
mutations have been reported in up to 65% of patients with spor-
adic disease [6–8]. About half of all somatic RET mutations are
the M918T point mutation, which is associated with poor prog-
nosis [8, 9]. In patients with sporadic MTC lacking RET muta-
tions, RAS gene mutations are common, occurring in up to 68%
of cases [7, 10, 11]. In addition, the vascular endothelial growth
factor and MET pathways are thought to promote angiogenesis,
invasion, and metastasis in MTC [3, 12, 13].
Chemotherapy has limited activity in patients with unresect-
able or metastatic MTC [3]. More recently, multitargeted kinase
inhibitors (MKIs) have been approved for locally advanced or
metastatic MTC [6, 14].
Cabozantinib, an inhibitor of kinases, including MET, vascular
endothelial growth factor receptors, and RET [15], is approved in
the United States and Europe for progressive, metastatic MTC
based on findings of the EXAM trial (Trial Registration Number:
NCT00704730) [14]. In this phase III study, cabozantinib signifi-
cantly prolonged progression-free survival (PFS), the primary
end point, compared with placebo in patients with documented
radiographic progression of metastatic MTC (estimated median
PFS 11.2 versus 4.0 months; hazard ratio [HR], 0.28; 95% confi-
dence interval [CI], 0.19–0.40; P< 0.001) [14]. At the primary
analysis, a planned interim analysis of OS showed no difference
between treatment arms (HR, 0.98; 95% CI, 0.63–1.52), but only
96 of the planned 217 deaths for the final analysis had occurred.
We report here the final OS analysis for the EXAM trial after
additional follow-up and include updated safety data after long-
term treatment with cabozantinib.
Patients and methods
Study design and patients
The EXAM study design has been described previously [14]. In brief,
EXAM was an international, double-blind, randomized, placebo-
controlled phase III study evaluating cabozantinib in adult patients with
unresectable locally advanced or metastatic MTC. Patients were required
to have documented radiographic disease progression per Response
Evaluation Criteria in Solid Tumors guidelines version 1.0 at screening
compared with images obtained within the prior 14 months. No limit
was placed on number of prior therapies, including MKIs. All patients
provided written informed consent. The protocol was approved by ethics
committees or institutional boards at each clinical site, nationally, or
both.
The primary end point was PFS [14]. Key secondary end points were
objective response rate (ORR), OS, and assessment of the relationship be-
tween RET mutation status and efficacy of cabozantinib [14]. Mutations
in the RET gene (exons 10, 11, and 13–16) were identified from blood
and archival tumor samples using Sanger and next-generation sequenc-
ing methods [14, 16], and a subset of tumor samples not harboring RET
mutations was also analyzed for mutations in HRAS, KRAS, and NRAS at
codons 12, 13, and 61 [14, 16].
Randomization and treatment
Patients were randomized to receive cabozantinib or placebo (2:1) strati-
fied by age (65 and>65 years) and prior MKI treatment (yes, no) [14].
Patients received cabozantinib (140 mg/day) or placebo administered or-
ally until intolerable toxicity or disease progression per Response
Evaluation Criteria in Solid Tumors version 1.0. The study was un-
blinded after the primary analysis of PFS. Patients receiving placebo were
not allowed to crossover to cabozantinib.
Overall survival analysis
An interim OS analysis was planned at the time of the primary PFS ana-
lysis. The final OS analysis was to be conducted after at least 217 deaths
were observed in the intent-to-treat population. This provided 80%
power to detect an HR of 0.667 using the log-rank test and a 2-sided sig-
nificance level of 4% (allocated at interim and final analyses per an alpha
spending function), corresponding to a 33.3% reduction in rate of death
or a 50% increase in median survival from 22 to 33 months.
Median OS was estimated using the Kaplan–Meier method. For pa-
tients who were alive at the time of data cutoff for the current analysis (28
August 2014) or who were lost to follow-up, the duration of OS was right
censored at the date the patient was last known to be alive. Testing be-
tween the two treatment arms was carried out by the stratified log-rank
test using randomization stratification factors. The HR was estimated
using a Cox regression model with treatment group as the main effect
and included the randomization stratification factors. In an exploratory
subgroup analysis, we assessed OS and PFS by baseline demographics and
characteristics, and RET and RAS mutation status. Analyses on the basis
of RET mutation status were pre-specified (RET mutation–positive, RET
mutation–negative, and RET mutation–unknown subgroups), while
analyses based on RAS mutation status or the presence of the RET
M918T mutation were post hoc. The primary analysis data cut-off of 6
April 2011 was used for all PFS analyses. Calculated P values for sub-
groups are descriptive only.
Safety analysis
Safety assessments included evaluation of adverse events (AEs), serious
AEs (SAEs), deaths, standard laboratory tests, physical examinations, and
electrocardiograms. Severity of AEs was based on National Cancer
Institute’s Common Terminology Criteria for Adverse Events, version 3.
SAEs were defined in accordance with International Conference on
Harmonisation Guidelines for Clinical Safety Data Management (1994).
Results
Patients
At data cut-off (28 August 2014), 10% (21/219) of patients in the
cabozantinib group were still receiving treatment; all patients in
the placebo group had discontinued (supplementary Figure S1,
available at Annals of Oncology online). Detailed baseline
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characteristics of the randomized patients were balanced between
arms [14]. Briefly, 40% of all patients (n¼ 133) had received
prior anticancer therapy, and 21% (n¼ 68) prior MKI treatment.
One quarter (25%) of patients (n¼ 83) had received2 systemic
therapies. The main sites of metastases were lymph nodes, liver,
lung, and bone. RET and RAS mutational status are summarized
in supplementary Table S1, available atAnnals of Oncology online.
Apart from mutational status, RET subgroups showed similar
baseline characteristics (supplementary Table S2, available at
Annals of Oncology online).
OS and PFS
In this OS analysis, 64% (141/219) of patients in the cabozantinib
arm and 69% (77/111) in the placebo arm had died. Minimum
follow-up was 42 months. There was a 5.5-month numerical
increase in median OS with cabozantinib versus placebo (26.6
versus 21.1 months). However, this difference did not reach stat-
istical significance (stratified HR, 0.85; 95% CI, 0.64–1.12;
P¼ 0.24) (Figure 1A).
OS and PFS data were assessed in subgroups, including RET
mutation status, RET M918T mutation status, and RAS mutation
status (Figures 1B and C and 2), as well as demographics and
baseline characteristics (supplementary Figure S2, available at
Annals of Oncology online). Cabozantinib was favored over pla-
cebo for both OS and PFS in patients with and without RET mu-
tations and for those with an unknown RET mutation status.
There was a substantial OS benefit associated with cabozantinib
in the RET M918T–positive subgroup with a median OS of 44.3
versus 18.9 months for placebo [HR, 0.60; 95% CI, 0.38–0.94;
P¼ 0.03 (not adjusted for multiple subgroup analyses)]. PFS in
the RET M918T–positive subgroup were consistent with OS,
favoring cabozantinib (HR, 0.15; 95% CI 0.08–0.28; P<0.0001).
For the RET M918T–negative subgroup, there was no OS benefit
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P value 0.63
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11.2 4.0
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Placebo
Cabozantinib Placebo
Cabozantinib Placebo
(n=45)
Median PFS, mo 13.9 4.0
HR (95% CI) 0.15 (0.08, 0.28)
P value
Median PFS, mo
HR (95% CI)
P value
<0.0001
(n=75) (n=32)
5.7 5.4
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Figure 1. Kaplan–Meier curve of overall survival (OS) and progression-free survival (PFS) in the (A) overall intent-to-treat population, (B) in pa-
tients with RET M918T–positive disease, and (C) in patients with RET M918T–negative disease. Data cut-off was 28 August 2014 for OS and 6
April 2011 for PFS. aAnalyses for (A) were stratified by randomization stratification factors, and analyses of subgroups (B and C) were unstrati-
fied. HR, hazard ratio; CI, confidence interval. P values were not adjusted for multiple comparisons. Methods for determining RET M918T status
are described elsewhere [16].
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with cabozantinib (HR, 1.12; 95% CI, 0.70–1.82; P¼ 0.63),
whereas there was a trend toward improved PFS that did not
reach statistical significance (HR, 0.67; 95% CI, 0.37–1.23;
P¼ 0.19). At the time of the primary analysis (cut-off of 6 April
2011), the ORR for patients receiving cabozantinib was 28%
overall, 34% for the RET M918T–positive subgroup, and 20% for
the RET M918T–negative subgroup. There were no responses in
the placebo arm.
Subgroup analysis of patients harboring RAS mutations
showed a trend toward improved OS (HR, 0.37; 95% CI, 0.10–
1.42) and PFS (HR, 0.15; 95% CI, 0.02–1.10). However, this was a
small subgroup (13 patients in the cabozantinib arm and three in
the placebo arm) and differences between arms were not statistic-
ally significant.
Subsequent anticancer therapy
The percentage of patients who received any subsequent antican-
cer therapy was 44% (32% systemic therapy) in the cabozantinib
group and 58% (50% systemic therapy) in the placebo group
(supplementary Table S3, available at Annals of Oncology online).
MKIs were frequently used as subsequent systemic therapy (27%
in the cabozantinib group, 41% in the placebo group). For pa-
tients receiving subsequent therapy, there was no OS benefit with
cabozantinib versus placebo (HR, 0.93; 95% CI, 0.63–1.39), while
cabozantinib was favored in patients who did not receive subse-
quent therapy (HR, 0.59; 95% CI, 0.39–0.88) (supplementary
Figure S2, available atAnnals of Oncology online).
Safety
Median duration of exposure to cabozantinib was 10.8 months
(interquartile range, 3.3–25.1 months) with 25% receiving cabo-
zantinib for >2 years. This was more than three times that of
the placebo arm (median 3.4 months; interquartile range,
3.0–6.5 months). The proportion of cabozantinib-treated
patients who had a dose reduction was 82%, and 46% underwent
a second-level dose reduction.
Safety data have been updated through the 28 August 2014 cut-
off. AEs reported in20% of patients are summarized in Table 1
(supplementary Table S4, available at Annals of Oncology online
for AEs reported in10%). The types and rates of AEs in this
updated analysis remained consistent with the PFS analysis [14].
The most frequently reported SAEs (2%) in the cabozantinib
arm were pneumonia (4.2% versus 3.7% in the placebo arm),
pulmonary embolism (3.3% versus 0%), hypocalcemia (2.8%
versus 0%), mucosal inflammation (2.8% versus 0%), dehydra-
tion (2.3% versus 0.9%), dysphagia (2.3% versus 1.8%), hyper-
tension (2.3% versus 0%), and lung abscess (2.3% versus 0%).
Grade 5 AEs that occurred before the 15 June 2011 data cut-off
were reported in the primary analysis [14]. During the additional
follow-up, six patients in the cabozantinib arm died while on
study treatment or within 30 days of the last dose. One of these
was considered related to study treatment (esophageal bleeding
for a patient on treatment for 381 days). The other grade 5 AEs
were considered unrelated to treatment and included multiorgan
failure (one patient on treatment for 542 days), bronchopneumo-
nia (one patient on treatment for 705 days), general physical
health deterioration (two patients on treatment for 674 and
1324 days), and respiratory failure (one patient on treatment for
785 days).
Discussion
In this updated analysis of the phase III EXAM trial in patients
with progressive, metastatic MTC, the secondary end point of im-
proved OS was not reached. Median OS was 5.5 months longer
with cabozantinib versus placebo, but this did not achieve statis-
tical significance. In exploratory analyses of OS, PFS, and ORR,
cabozantinib appeared to be more active in patients who were
RET M918T positive than in those who were RET M918T
Patients
Cabozantinib/Placebo HR (95% CI) HR (95% CI)
Overall survival Progression-free survival
All patientsa 219/111 0.85 (0.64, 1.12) 0.28 (0.19, 0.40)
0.79 (0.54, 1.17) 0.23 (0.14, 0.38)107/62Positive
0.68 (0.33, 1.38) 0.53 (0.19, 1.50)35/11Negative
0.91 (0.56, 1.48) 0.30 (0.16, 0.57)77/38Unknown
0.60 (0.38, 0.94) 0.15 (0.08, 0.28)81/45Positive
1.12 (0.70, 1.82) 0.67 (0.37, 1.23)75/32Negative
0.92 (0.54, 1.56) 0.27 (0.13, 0.56)63/34Unknown
RET M918T status
RET mutation status
RAS mutation status 
13/3 0.37 (0.10, 1.42) 0.15 (0.02, 1.10)Positive
Favors
cabozantinib
Favors 
placebo
Favors
cabozantinib
Favors 
placebo
0.0625 0.25 1 4 0.0625 0.25 1 4
Figure 2. Subgroup analysis of overall survival and progression-free survival (PFS) according to RET mutation status, RET M918T status, and
RAS mutations status. Data cut-off was 28 August 2014 for overall survival and 6 April 2011 for PFS. aAnalyses for all patients were stratified by
randomization stratification factors, and analyses of subgroups were unstratified. HR, hazard ratio; CI, confidence interval. Methods for deter-
mining RET and RAS mutation status are described elsewhere [16].
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negative. For RET M918T–positive patients, median OS was
44.3 months for cabozantinib versus 18.9 months for placebo.
In the primary analysis of this trial, the primary end point of
improved PFS was met. Median PFS with cabozantinib was
11.2 months compared with 4.0 months for placebo (HR, 0.28;
95% CI, 0.19–0.40; P<0.001) [14]. RET M918T–positive patients
had longer PFS and higher ORR versus RET M918T–negative pa-
tients. OS results appear to be consistent with PFS but are limited
because of the sample size. The trial was designed with reasonable
power (80%) for OS as a secondary end point provided that cabo-
zantinib treatment resulted in a large benefit (50% increase)
based on study size. Because MTC is relatively rare, the feasibility
of designing a trial assuming a more modest but clinically rele-
vant OS benefit is not practical. In addition, the use of subsequent
systemic anticancer therapy (38% of patients in the cabozantinib
arm versus 50% of patients in the placebo arm) may also have im-
pacted the OS results.
The OS findings in patients harboring an RET M918T muta-
tion are of clinical interest although these are exploratory data.
RET M918T has been associated with poorer prognosis for pa-
tients with sporadic disease and the most rapid course of disease
development for patients with hereditary disease [8, 9]. The
mechanisms by which patients with RET M918T–positive tumors
would respond better to cabozantinib than those with RET
M918T–negative tumors have not been characterized. However,
cabozantinib’s mechanism of action and the biochemical impact
of the RET M918T mutation provide insight into the potential
etiology. Possible contributing factors include the effects of the
mutation of RET signaling, and its sensitivity to inhibition by
cabozantinib. The M918T mutation in the RET kinase domain
has been shown to increase its catalytic activity [17]. Differences
in downstream signaling between RET M918T and other RET
isoforms have also been noted [18, 19], including enhanced acti-
vation of the RAS signaling pathway. The high catalytic activity of
the M918T isoform and its strong ability to activate signaling in
crucial downstream pathways may promote higher ‘oncogene ad-
diction’ to RET and greater sensitivity to RET inhibition [20].
Cabozantinib is a potent inhibitor of RET, including the wild-
type and M918T isoforms [21].
In contrast to the cabozantinib arm, the difference in OS between
RET M918T–positive and RET M918T–negative patients who were
randomized to the placebo arm was less notable (<3 months) des-
pite previously reported association ofRETM918T with poor prog-
nosis [8, 9]. This may be attributable to all patients in the EXAM
study having advanced progressive disease at study entry.
The results of this current analysis suggest that identification
of tumors bearing somatic RET M918T mutations may be a pre-
dictive biomarker for progressive MTC, but this will require
confirmation and validation. Further, determination of RET
mutational status in the clinical setting presents challenges.
There are technical limitations to sequencing, and mutations
may be present in only some lesions or at later disease stages
Table 1. Adverse events occurring in20% of cabozantinib-treated patients regardless of causality by maximum severity reporting
Cabozantinib Placebo
N5 214 N5109
Grade, n (%) Grade, n (%)
All 3 All 3
Diarrhea 150 (70.1) 46 (21.5) 39 (35.8) 2 (1.8)
Weight decreased 124 (57.9) 21 (9.8) 12 (11.0) 0
Palmar-plantar erythrodysesthesia syndrome 113 (52.8) 27 (12.6) 2 (1.8) 0
Decreased appetite 105 (49.1) 15 (7.0) 17 (15.6) 1 (0.9)
Nausea 100 (46.7) 4 (1.9) 23 (21.1) 0
Fatigue 91 (42.5) 21 (9.8) 33 (30.3) 3 (2.8)
Dysgeusia 75 (35.0) 1 (0.5) 6 (5.5) 0
Hair color changes 73 (34.1) 1 (0.5) 1 (0.9) 0
Hypertension 70 (32.7) 19 (8.9) 5 (4.6) 0
Stomatitis 64 (29.9) 5 (2.3) 3 (2.8) 0
Constipation 60 (28.0) 0 6 (5.5) 0
Vomiting 56 (26.2) 5 (2.3) 2 (1.8) 1 (0.9)
Mucosal inflammation 54 (25.2) 7 (3.3) 4 (3.7) 0
Asthenia 53 (24.8) 14 (6.5) 16 (14.7) 2 (1.8)
Alanine aminotransferase increased 52 (24.3) 11 (5.1) 6 (5.5) 2 (1.8)
Aspartate aminotransferase increased 51 (23.8) 4 (1.9) 6 (5.5) 0
Hypocalcemia 51 (23.8) 23 (10.7) 5 (4.6) 0
Rash 49 (22.9) 2 (0.9) 11 (10.1) 0
Back pain 47 (22.0) 9 (4.2) 16 (14.7) 1 (0.9)
Dysphonia 47 (22.0) 0 11 (10.1) 0
Abdominal pain 47 (22.0) 7 (3.3) 8 (7.3) 1 (0.9)
Pain in extremity 45 (21.0) 4 (1.9) 13 (11.9) 1 (0.9)
Dry skin 43 (20.1) 0 3 (2.8) 0
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[22]. Given these caveats and the activity of cabozantinib in the
RET M918T–negative group with respect to PFS and ORR,
patients with progressive MTC should not be excluded from
cabozantinib treatment based solely on tumor genotype.
There were no new or unexpected signals in the updated safety
data for patients treated with cabozantinib, some of whom re-
mained on treatment for extended periods—25% of patients
received cabozantinib for >2 years [14]. The majority of patients
underwent dose reductions, suggesting that with appropriate
dose reductions and AE management, patients can maintain
long-term treatment with cabozantinib. The study of cabozanti-
nib in MTC is continuing, including a trial comparing the 140-
mg starting dose in capsules to a 60-mg starting dose in tablets
(ClinicalTrials.gov NCT01896479). This study will also evaluate
the relationship of RET M918T status with clinical activity.
In conclusion, in this final analysis of OS from the EXAM trial,
the secondary end point of OS was not met. A statistically non-
significant increase in OS of 5.5 months was observed for cabo-
zantinib compared with placebo in patients with metastatic MTC
with documented radiographic progression. Among subgroups,
the largest OS benefit was observed in RET M918T–positive pa-
tients. After extended treatment, the cabozantinib safety profile
remained consistent with that reported in the primary analysis.
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